CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
90.18
1.28%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.20
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Edwards Lifesciences Corp ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 91.35
Open* 90.22
1-Year Change* 10.01%
Day's Range* 89.3 - 90.3
52 wk Range 60.57-94.87
Average Volume (10 days) 3.09M
Average Volume (3 months) 92.95M
Market Cap 45.15B
P/E Ratio 31.83
Shares Outstanding 606.50M
Revenue 5.82B
EPS 2.34
Dividend (Yield %) N/A
Beta 1.04
Next Earnings Date Feb 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 90.18 -0.37 -0.41% 90.55 90.63 89.27
Apr 11, 2024 91.35 -0.96 -1.04% 92.31 92.45 90.91
Apr 10, 2024 91.41 0.16 0.18% 91.25 91.83 90.72
Apr 9, 2024 93.01 1.37 1.49% 91.64 93.05 91.07
Apr 8, 2024 92.32 0.12 0.13% 92.20 92.78 91.39
Apr 5, 2024 92.62 1.47 1.61% 91.15 92.87 90.60
Apr 4, 2024 91.10 -2.24 -2.40% 93.34 94.16 91.06
Apr 3, 2024 92.96 -0.74 -0.79% 93.70 94.98 92.69
Apr 2, 2024 94.21 1.35 1.45% 92.86 94.35 92.26
Apr 1, 2024 94.15 -0.62 -0.65% 94.77 95.11 93.22
Mar 28, 2024 95.48 0.20 0.21% 95.28 95.98 94.77
Mar 27, 2024 95.09 1.63 1.74% 93.46 95.29 93.16
Mar 26, 2024 93.32 0.20 0.21% 93.12 94.26 93.12
Mar 25, 2024 93.09 -0.86 -0.92% 93.95 94.27 92.88
Mar 22, 2024 93.72 -0.32 -0.34% 94.04 94.75 93.13
Mar 21, 2024 94.62 0.95 1.01% 93.67 95.12 93.55
Mar 20, 2024 92.94 -0.93 -0.99% 93.87 94.23 91.90
Mar 19, 2024 94.15 1.90 2.06% 92.25 94.39 92.04
Mar 18, 2024 92.82 0.67 0.73% 92.15 92.98 91.83
Mar 15, 2024 92.24 0.02 0.02% 92.22 93.93 92.10

Edwards Lifesciences Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Edwards Lifesciences Corp Earnings Release
Q1 2024 Edwards Lifesciences Corp Earnings Release

Forecast

-

Previous

-

Time (UTC)

21:00

Country

US

Event

Q1 2024 Edwards Lifesciences Corp Earnings Call
Q1 2024 Edwards Lifesciences Corp Earnings Call

Forecast

-

Previous

-
Tuesday, May 7, 2024

Time (UTC)

17:00

Country

US

Event

Edwards Lifesciences Corp Annual Shareholders Meeting
Edwards Lifesciences Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Friday, May 10, 2024

Time (UTC)

17:00

Country

US

Event

Edwards Lifesciences Corp Annual Shareholders Meeting
Edwards Lifesciences Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, July 24, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Edwards Lifesciences Corp Earnings Release
Q2 2024 Edwards Lifesciences Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 5382.4 5232.5 4386.3 4348 3722.8
Revenue 5382.4 5232.5 4386.3 4348 3722.8
Cost of Revenue, Total 1080.4 1248.9 1080.6 1114.4 939.4
Gross Profit 4302 3983.6 3305.7 3233.6 2783.4
Total Operating Expense 3630.1 3542.2 3488.7 3201.2 2967.5
Selling/General/Admin. Expenses, Total 1567.6 1493.7 1228.4 1240.2 1088.5
Research & Development 945.2 903.1 760.7 752.7 622.2
Interest Expense (Income) - Net Operating
Unusual Expense (Income) 72.7 20.6 405.4 100 323.1
Other Operating Expenses, Total -35.8 -124.1 13.6 -6.1 -5.7
Operating Income 1752.3 1690.3 897.6 1146.8 755.3
Net Income Before Taxes 1767.4 1702 916.7 1166.5 761.4
Net Income After Taxes 1521.9 1503.1 823.4 1049.7 738
Net Income Before Extra. Items 1521.9 1503.1 823.4 1049.7 738
Net Income 1521.9 1503.1 823.4 1046.9 722.2
Income Available to Common Excl. Extra. Items 1521.9 1503.1 823.4 1049.7 738
Income Available to Common Incl. Extra. Items 1521.9 1503.1 823.4 1046.9 722.2
Diluted Net Income 1521.9 1503.1 823.4 1046.9 722.2
Diluted Weighted Average Shares 624.2 631.2 631.9 636.606 640.806
Diluted EPS Excluding Extraordinary Items 2.43816 2.38134 1.30305 1.6489 1.15167
Diluted Normalized EPS 2.53845 2.41016 1.87932 1.79025 1.64039
Total Extraordinary Items -2.8 -15.8
Interest Income (Expense), Net Non-Operating 14 9.8 20.5 21.3 17.3
Other, Net 1.1 1.9 -1.4 -1.6 -11.2
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 1480.9 1530.2 1459.6 1348.3 1319
Revenue 1480.9 1530.2 1459.6 1348.3 1319
Cost of Revenue, Total 350.4 343 329.5 257.9 252.2
Gross Profit 1130.5 1187.2 1130.1 1090.4 1066.8
Total Operating Expense 1062.5 1203 1071.2 900.5 916.6
Selling/General/Admin. Expenses, Total 439.6 468.7 436.3 411 377.3
Research & Development 270.3 270.3 261.2 232.2 233.6
Unusual Expense (Income) 2.2 147.9 43.5 -1.1 66
Other Operating Expenses, Total 0 -26.9 0.7 0.5 -12.5
Operating Income 418.4 327.2 388.4 447.8 402.4
Interest Income (Expense), Net Non-Operating 15.1 11.3 10 11.6 5.3
Other, Net 5.8 0 0.2 -0.1 -0.4
Net Income Before Taxes 439.3 338.5 398.6 459.3 407.3
Net Income After Taxes 383.7 305.5 340.5 398.4 343.5
Net Income Before Extra. Items 384.9 307.1 340.5 398.4 343.5
Net Income 384.9 307.1 340.5 398.4 343.5
Income Available to Common Excl. Extra. Items 384.9 307.1 340.5 398.4 343.5
Income Available to Common Incl. Extra. Items 384.9 307.1 340.5 398.4 343.5
Diluted Net Income 384.9 307.1 340.5 398.4 343.5
Diluted Weighted Average Shares 609.5 610.3 610.9 616.1 624.5
Diluted EPS Excluding Extraordinary Items 0.6315 0.5032 0.55737 0.64665 0.55004
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS 0.63465 0.72191 0.6182 0.6451 0.63917
Minority Interest 1.2 1.6
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 3095.8 3180.7 3091 2984 2286.9
Cash and Short Term Investments 1215.3 1466.8 1402.6 1516.9 956.5
Cash & Equivalents 769 862.8 1183.2 1179.1 714.1
Short Term Investments 446.3 604 219.4 337.8 242.4
Total Receivables, Net 699.1 664.9 602.8 599.1 537.3
Accounts Receivable - Trade, Net 643 582.2 514.6 543.6 456.9
Total Inventory 875.5 726.7 802.3 640.9 607
Prepaid Expenses 110 85.2 75.1 59.1 54.3
Other Current Assets, Total 195.9 237.1 208.2 168 131.8
Total Assets 8292.5 8502.6 7237.1 6488.1 5323.7
Property/Plant/Equipment, Total - Net 1725.1 1638.7 1489.4 1140.4 867.5
Goodwill, Net 1164.3 1167.9 1173.2 1167.7 1112.2
Intangibles, Net 285.2 323.6 331.4 336.5 343.2
Long Term Investments 1239 1834.2 801.6 585.5 506.3
Other Long Term Assets, Total 783.1 357.5 350.5 274 207.6
Total Current Liabilities 1022.4 1032.3 893.9 902.4 876.6
Accounts Payable 201.9 204.5 196.5 180.4 134
Accrued Expenses 667.8 714.2 578.7 642.7 510.2
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 152.7 113.6 118.7 79.3 232.4
Total Liabilities 2485.8 2666.7 2662.8 2339.8 2183.3
Total Long Term Debt 596.3 595.7 595 594.4 593.8
Long Term Debt 596.3 595.7 595 594.4 593.8
Other Liabilities, Total 867.1 1038.7 1173.9 843 712.9
Total Equity 5806.7 5835.9 4574.3 4148.3 3140.4
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 646.3 642 636.4 218.1 215.2
Additional Paid-In Capital 1969.3 1700.4 1438.1 1623.3 1384.4
Retained Earnings (Accumulated Deficit) 7590 6068.1 4565 3741.6 2694.7
Treasury Stock - Common -4144 -2416.9 -1904.1 -1278.7 -1015.4
Other Equity, Total -189.3 -150.8 -169.7 -157.7 -133.5
Total Liabilities & Shareholders’ Equity 8292.5 8502.6 7237.1 6488.1 5323.7
Total Common Shares Outstanding 608.3 624.1 624.3 627.306 623.106
Current Port. of LT Debt/Capital Leases 0 0 0
Unrealized Gain (Loss) -65.6 -6.9 8.6 1.7 -5
Property/Plant/Equipment, Total - Gross 2475.5 2293.3 2087.9 1652.7 1322.8
Accumulated Depreciation, Total -750.4 -654.6 -598.5 -512.3 -455.3
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 4067.5 3647 3257.2 3095.8 3513.9
Cash and Short Term Investments 1863.9 1509.3 1254.2 1215.3 1738.7
Cash & Equivalents 1410.1 1042.6 872.5 769 1247.8
Short Term Investments 453.8 466.7 381.7 446.3 490.9
Total Receivables, Net 802.1 816.9 779.3 699.1 661.4
Accounts Receivable - Trade, Net 739.8 754.4 717.7 643 618.1
Total Inventory 1032.4 980.2 914.3 875.5 757.8
Prepaid Expenses 133.3 123.2 119.1 110 88.4
Other Current Assets, Total 235.8 217.4 190.3 195.9 267.6
Total Assets 9370.8 9004 8651.2 8292.5 8638.2
Property/Plant/Equipment, Total - Net 1772.2 1747.1 1734.5 1725.1 1654.1
Goodwill, Net 1297.4 1299.5 1308.4 1164.3 1158.7
Intangibles, Net 429.8 431.4 446.8 285.2 266.5
Long Term Investments 704.6 856.2 1066.7 1239 1381
Other Long Term Assets, Total 1099.3 1022.8 837.6 783.1 664
Total Current Liabilities 1238.9 1157.2 1082 1022.4 917.9
Accounts Payable 190.6 193 180.8 201.9 154.9
Accrued Expenses 773.3 740.2 727.9 667.8 638.9
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 275 224 173.3 152.7 124.1
Total Liabilities 2713.3 2628.3 2673.2 2485.8 2420.4
Total Long Term Debt 596.8 596.7 596.5 596.3 596.2
Long Term Debt 596.8 596.7 596.5 596.3 596.2
Deferred Income Tax
Other Liabilities, Total 808 803.6 910.7 867.1 906.3
Total Equity 6657.5 6375.7 5978 5806.7 6217.8
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 649.9 649.1 647.1 646.3 645.7
Additional Paid-In Capital 2211.3 2145.5 2049.3 1969.3 1914.5
Retained Earnings (Accumulated Deficit) 8622.5 8237.6 7930.5 7590 7191.6
Treasury Stock - Common -4576.1 -4401 -4393.5 -4144 -3278
Unrealized Gain (Loss) -36.1 -46.7 -52.6 -65.6 -75.4
Other Equity, Total -214 -208.8 -202.8 -189.3 -180.6
Total Liabilities & Shareholders’ Equity 9370.8 9004 8651.2 8292.5 8638.2
Total Common Shares Outstanding 606.5 607.9 606 608.3 619.4
Minority Interest 69.6 70.8 84
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 1521.9 1503.1 823.4 1046.9 722.2
Cash From Operating Activities 1218.2 1732.1 1054.3 1179.4 926.8
Cash From Operating Activities 139.6 134.8 107.2 89.3 77.4
Deferred Taxes -254.5 -41.4 -49.4 12.1 -27.3
Non-Cash Items 232.6 -9.7 130.9 235.4 197.1
Cash Taxes Paid 504.1 182.5 197.9 61.5 223.7
Cash Interest Paid 19.3 20.2 19.9 19.9 30.1
Changes in Working Capital -421.4 145.3 42.2 -204.3 -42.6
Cash From Investing Activities 252.3 -1722.5 -531.1 -595.8 76.7
Capital Expenditures -264.8 -329.8 -407.3 -278.4 -241.7
Other Investing Cash Flow Items, Total 517.1 -1392.7 -123.8 -317.4 318.4
Cash From Financing Activities -1584.5 -356.3 -486.9 -115.6 -1101.2
Financing Cash Flow Items -3.6 -0.3 -1.2 -2.8 -15.4
Issuance (Retirement) of Stock, Net -1580.7 -354.2 -484.9 -102.8 -648.5
Issuance (Retirement) of Debt, Net -0.2 -1.8 -0.8 -10 -437.3
Foreign Exchange Effects 19.2 13.9 -20.5 -3 -6.5
Net Change in Cash -94.8 -332.8 15.8 465 -104.2
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 340.5 1521.9 1123.5 780 373.6
Cash From Operating Activities 314.1 1218.2 935.4 625.5 293.3
Cash From Operating Activities 35.2 139.6 104.2 68.8 34.7
Deferred Taxes -51.8 -254.5 -148.7 -102.4 -42.6
Non-Cash Items 46.8 232.6 192.9 101.1 57
Changes in Working Capital -56.6 -421.4 -336.5 -222 -129.4
Cash From Investing Activities 0.5 252.3 157.6 359.1 229.5
Capital Expenditures -61.5 -264.8 -175.7 -115.8 -72.7
Other Investing Cash Flow Items, Total 62 517.1 333.3 474.9 302.2
Cash From Financing Activities -206.6 -1584.5 -746.1 -676.2 -368.1
Financing Cash Flow Items 0.8 -3.6 -3.8 -1.9 0
Issuance (Retirement) of Stock, Net -207.4 -1580.7 -742.2 -674.2 -368.1
Issuance (Retirement) of Debt, Net -0.2 -0.1 -0.1 0
Foreign Exchange Effects -4.2 19.2 37.4 27.1 13.2
Net Change in Cash 103.8 -94.8 384.3 335.5 167.9

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Edwards Lifesciences Company profile

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Edwards Lifesciences Corp revenues increased 19% to $5.23B. Net income increased 83% to $1.5B. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 20% to $3.42B, Surgical Heart Valve Therapy segment increase of 17% to $889.1M, Critical Care segment increase of 15% to $834.9M, United States segment increase of 18% to $2.96B, Europe segment increase of 26% to $1.19B.

Equity composition

Common Stock $1 Par, 12/10, 350M auth., 117,100,000 issd. less 2,000 shs. in Treas. @ $102M. Insiders control 0.64%. 4/3/00,Company spun off from Baxter International. 05/10, 2-for-1 stock split. 12/15, 2-for-1 stock split.

Industry: Advanced Medical Equipment & Technology (NEC)

One Edwards Way
IRVINE
CALIFORNIA 92614
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

ETH/USD

3,024.99 Price
+3.810% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,006.40 Price
-1.660% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.49 Price
+12.120% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,344.52 Price
-1.190% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading